CY1123900T1 - Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης - Google Patents
Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασηςInfo
- Publication number
- CY1123900T1 CY1123900T1 CY20211100151T CY211100151T CY1123900T1 CY 1123900 T1 CY1123900 T1 CY 1123900T1 CY 20211100151 T CY20211100151 T CY 20211100151T CY 211100151 T CY211100151 T CY 211100151T CY 1123900 T1 CY1123900 T1 CY 1123900T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mammal
- treatment
- pulmonary hypertension
- arterial hypertension
- pulmonary arterial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Παρέχεται μια μέθοδος μείωσης της πνευμονικής αρτηριακής υπέρτασης σε ένα θηλαστικό που χρησιμοποιεί FK506. Σε ορισμένες εφαρμογές, η μέθοδος περιλαμβάνει χορήγηση FK506 σε ένα θηλαστικό που έχει πνευμονική αρτηριακή υπέρταση που σχετίζεται με ελαττωματική σηματοδότηση MBPR2 σε μια δοσολογία επαρκή για τη μείωση της αρτηριακής πίεσης στην πνευμονική αρτηρία του θηλαστικού.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481317P | 2011-05-02 | 2011-05-02 | |
| PCT/US2012/035793 WO2012151153A1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123900T1 true CY1123900T1 (el) | 2022-05-27 |
Family
ID=47108011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100151T CY1123900T1 (el) | 2011-05-02 | 2021-02-23 | Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9474745B2 (el) |
| EP (3) | EP3821891B1 (el) |
| JP (1) | JP6177765B2 (el) |
| AU (2) | AU2012250974B9 (el) |
| CA (1) | CA2834368C (el) |
| CY (1) | CY1123900T1 (el) |
| DK (2) | DK2704711T3 (el) |
| ES (2) | ES2856173T3 (el) |
| FI (1) | FI3821891T3 (el) |
| HR (1) | HRP20210245T1 (el) |
| HU (1) | HUE053229T2 (el) |
| LT (1) | LT2704711T (el) |
| PL (1) | PL2704711T3 (el) |
| PT (2) | PT3821891T (el) |
| RS (1) | RS61480B1 (el) |
| SI (1) | SI2704711T1 (el) |
| WO (1) | WO2012151153A1 (el) |
| ZA (1) | ZA201307905B (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2973114C (en) * | 2015-01-13 | 2023-04-04 | Vivus, Inc. | Combination therapy for pulmonary hypertension |
| MX2017014301A (es) * | 2015-05-08 | 2018-03-23 | Vivus Inc | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. |
| CN108070566A (zh) * | 2015-08-05 | 2018-05-25 | 中国医学科学院基础医学研究所 | 肺动脉高压治疗药物的干细胞筛选模型及应用 |
| ES2683921B1 (es) * | 2017-03-28 | 2019-04-22 | Univ Vigo | Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar |
| CA3064275A1 (en) * | 2017-05-19 | 2018-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzastaurin and fragile histidine triad (fhit)-increasing agents for the treatment of pulmonary hypertension |
| WO2019185708A1 (en) * | 2018-03-28 | 2019-10-03 | Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prevention or treatment of chronic organ injury |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| DK2001466T3 (en) | 2006-03-23 | 2016-02-29 | Santen Pharmaceutical Co Ltd | LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES |
| FR2936060B1 (fr) * | 2008-09-17 | 2010-11-19 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire. |
| EP2346511A2 (en) * | 2008-10-22 | 2011-07-27 | Sam Amer&Co., Inc. | Method for treating pulmonary arterial hypertension |
-
2012
- 2012-04-30 WO PCT/US2012/035793 patent/WO2012151153A1/en active Application Filing
- 2012-04-30 EP EP20211109.2A patent/EP3821891B1/en active Active
- 2012-04-30 ES ES12779354T patent/ES2856173T3/es active Active
- 2012-04-30 PL PL12779354T patent/PL2704711T3/pl unknown
- 2012-04-30 AU AU2012250974A patent/AU2012250974B9/en active Active
- 2012-04-30 LT LTEP12779354.5T patent/LT2704711T/lt unknown
- 2012-04-30 US US14/113,375 patent/US9474745B2/en active Active
- 2012-04-30 SI SI201231881T patent/SI2704711T1/sl unknown
- 2012-04-30 DK DK12779354.5T patent/DK2704711T3/da active
- 2012-04-30 ES ES20211109T patent/ES2954905T3/es active Active
- 2012-04-30 PT PT202111092T patent/PT3821891T/pt unknown
- 2012-04-30 FI FIEP20211109.2T patent/FI3821891T3/fi active
- 2012-04-30 JP JP2014509338A patent/JP6177765B2/ja active Active
- 2012-04-30 EP EP12779354.5A patent/EP2704711B1/en active Active
- 2012-04-30 HU HUE12779354A patent/HUE053229T2/hu unknown
- 2012-04-30 CA CA2834368A patent/CA2834368C/en active Active
- 2012-04-30 EP EP23177834.1A patent/EP4279130A3/en active Pending
- 2012-04-30 DK DK20211109.2T patent/DK3821891T3/da active
- 2012-04-30 PT PT127793545T patent/PT2704711T/pt unknown
- 2012-04-30 RS RS20210239A patent/RS61480B1/sr unknown
-
2013
- 2013-10-23 ZA ZA2013/07905A patent/ZA201307905B/en unknown
-
2016
- 2016-09-21 US US15/271,794 patent/US20170007585A1/en not_active Abandoned
-
2017
- 2017-08-03 AU AU2017210583A patent/AU2017210583B2/en active Active
- 2017-10-12 US US15/782,153 patent/US20180185340A1/en not_active Abandoned
-
2018
- 2018-11-21 US US16/198,242 patent/US20190091208A1/en not_active Abandoned
-
2020
- 2020-07-29 US US16/941,778 patent/US20220184042A1/en not_active Abandoned
-
2021
- 2021-02-12 HR HRP20210245TT patent/HRP20210245T1/hr unknown
- 2021-02-23 CY CY20211100151T patent/CY1123900T1/el unknown
-
2023
- 2023-01-06 US US18/151,028 patent/US20230404982A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123900T1 (el) | Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης | |
| EA201170465A1 (ru) | Способы лечения прогрессирующего множественного склероза | |
| EA201490546A1 (ru) | Замещенные аннелированные пиримидины и их применение | |
| CR11749A (es) | Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina | |
| EA201100335A8 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
| EA201400565A1 (ru) | Молекулы антител, имеющие специфичность в отношении ох40 человека | |
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| CY1119527T1 (el) | Συνθεση για την αναγεννηση φυσιολογικου ιστου απο ινωτικο ιστο | |
| CO6362012A2 (es) | Clohidarto de nalmefeno dihidratado | |
| CO6561789A2 (es) | Método de tratamiento | |
| RU2011126854A (ru) | Способ моделирования хронической сердечной недостаточности в эксперименте | |
| UA66725U (ru) | Способ лечения постэмболизационного синдрома у женщин с лейомиомой матки на фоне аденомиоза | |
| RU2011119393A (ru) | Способ лечения пациентов с хроническим геммороем путем латексного лигирования геморроидального узла | |
| UA48652U (ru) | Способ оценки эффективности лечения больных ишемической болезнью сердца со стенокардией и артериальной гипертензией спираприлом | |
| UA68459U (ru) | Способ оценки эффективности лечения s-метопрололом больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу | |
| UA59716U (ru) | Способ лечения ишемической болезни сердца у женщин с сопутствующей ренопаренхиматозной артериальной гипертензией | |
| UA75914U (uk) | Спосіб підготовки дистального русла для артеріальної реконструкції при хронічній критичній ішемії нижньої кінцівки | |
| UA68460U (ru) | Способ оценки эффективности лечения s-атенололом больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу | |
| CU20100225A7 (es) | Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina | |
| UA69733U (ru) | Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью | |
| UA70143U (uk) | Спосіб оцінки функціонального стану мікроциркуляторної системи | |
| RU2013151036A (ru) | Интраоперационный способ купирования спазма коронарных артерий в кардиохирургии | |
| PL396438A1 (pl) | Wykorzystanie melatoniny do wytwarzania leku do nowego zastosowania | |
| RU2009116087A (ru) | Способ медикаментозного снижения уровня оксидативного стресса у больных артериальной гипертензией | |
| UA72092U (ru) | Способ оценки эффективности лечения розувастатином больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу |